These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37818027)

  • 1. 18F-fluoro-2-deoxy-2-d-glucose PET-CT (FDG PET-CT) in staging of high-risk renal and urothelial bladder cancers (COPPER-T) trial protocol.
    Jena R; Bhargava P; Tripathi S; Taywade S; Yadav T; Sandhu AS; Singh M; Navriya SC; Bhirud DP; Aggarwal A; Choudhary GR
    BJUI Compass; 2023 Nov; 4(6):662-667. PubMed ID: 37818027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.
    Nayak B; Dogra PN; Naswa N; Kumar R
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):386-93. PubMed ID: 23179944
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Al-Zubaidi M; Viswambaram P; McCombie S; Liow E; Lenzo N; Ferguson T; Redfern AD; Gauci R; Hayne D
    BMJ Open; 2022 Apr; 12(4):e060478. PubMed ID: 35428649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
    Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
    BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorodeoxyglucose positron emission tomography (18F-FDG PET)-computed tomography (CT) in the initial staging of bladder cancer: a single institution experience.
    Shahait M; Abu-Hijlih R; Farkouh A; Obeidat S; Salah S; Abdlkadir AS; Al-Ibraheem A
    J Egypt Natl Canc Inst; 2023 Jul; 35(1):21. PubMed ID: 37455263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography scan on initial evaluation of head and neck squamous cell carcinoma: our experience at a tertiary care center in India.
    Nair S; Mohan S; Nilakantan A; Gupta A; Malik A; Gupta A
    World J Nucl Med; 2015; 14(1):19-24. PubMed ID: 25709540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review.
    Aydh A; Abufaraj M; Mori K; Quhal F; Pradere B; Motlagh RS; Mostafaei H; Karakiewicz PI; Shariat SF
    Arab J Urol; 2020 Dec; 19(1):59-66. PubMed ID: 33763249
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.
    Zattoni F; Incerti E; Colicchia M; Castellucci P; Panareo S; Picchio M; Fallanca F; Briganti A; Moschini M; Gallina A; Karnes JR; Lowe V; Fanti S; Schiavina R; Rambaldi I; Ficarra V; Evangelista L
    Abdom Radiol (NY); 2018 Sep; 43(9):2391-2399. PubMed ID: 29302738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Staging
    Voskuilen CS; van Gennep EJ; Einerhand SMH; Vegt E; Donswijk ML; Bruining A; van der Poel HG; Horenblas S; Hendricksen K; van Rhijn BWG; Mertens LS
    Eur Urol Oncol; 2022 Jun; 5(3):366-369. PubMed ID: 33583752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of
    Civelek AC; Niglio SA; Malayeri AA; Lin J; Gurram S; Chalfin HJ; Turkbey B; Valera V; Steinberg SM; Apolo AB
    Urol Oncol; 2021 Nov; 39(11):787.e17-787.e21. PubMed ID: 34140245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients.
    Nanni C; Zompatori M; Ambrosini V; Montesi V; Mezzetti S; Ferretti A; Chondrogiannis S; Rubello D; Fanti S
    Biomed Pharmacother; 2013 Mar; 67(2):172-8. PubMed ID: 23433901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer.
    Einerhand SMH; van Gennep EJ; Mertens LS; Hendricksen K; Donswijk ML; van der Poel HG; van Rhijn BWG
    Curr Opin Urol; 2020 Sep; 30(5):654-664. PubMed ID: 32701719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary on "Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle." Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam Hospital, Amsterdam, The Netherlands.: BJU Int 2013; 112(6):72934. doi:10.1111/bju.12109. [Epub 2013 Jun 24].
    See WA
    Urol Oncol; 2014 Nov; 32(8):1350. PubMed ID: 25488385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.
    Apolo AB; Riches J; Schöder H; Akin O; Trout A; Milowsky MI; Bajorin DF
    J Clin Oncol; 2010 Sep; 28(25):3973-8. PubMed ID: 20679618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Evaluation of FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder Cancer.
    Einerhand SMH; Voskuilen CS; van de Putte EEF; Donswijk ML; Bruining A; van der Heijden MS; Mertens LS; Hendricksen K; Vegt E; van Rhijn BWG
    Bladder Cancer; 2023; 9(1):49-57. PubMed ID: 38994487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
    Facey K; Bradbury I; Laking G; Payne E
    Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
    Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
    Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.